Save 20% on Press Releases and More with NNW Prime! Click to View Details
WednesdayJul 01, 2026 12:00 pm

The Next Battle in Space Isn’t Launching Satellites. It’s Managing Them.

Disseminated on behalf of Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) and may include paid advertising. SpaceX's record June 2026 IPO put a public spotlight on space, yet most of the sector's frontier companies remain private and out of reach for public investors Antaris, a software-defined space infrastructure company backed by Planet Ventures, signed a memorandum of agreement with Transcelestial to develop and flight-test a combined surveillance and optical-communications architecture on its JANUS-2 mission in late 2026 Planet Ventures gives public-market investors exposure to private space companies such as Antaris, Relativity Space, and General Astronautics that are typically accessible only…

Continue Reading

WednesdayJul 01, 2026 11:15 am

Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) Advances Santa Fe, Walker Lane amid Tightening Gold Supply Dynamics

Disseminated on behalf of  Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising. Top gold-producing countries are showing strain of widespread government, cost and environmental pressures. These pressures strengthen the case for secure, transparent and infrastructure-supported gold development in the United States. Existing mine infrastructure, historical production, oxide material and location in a leading U.S. gold state may give Lahontan’s Santa Fe project a different development profile. Global gold supply is entering a more complicated era, shaped not only by geology and discovery rates but also by government policy, rising operating costs, safety enforcement, environmental oversight and growing…

Continue Reading

WednesdayJul 01, 2026 10:40 am

Why VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals

Deal activity remains strong in antibody-drug conjugates (ADCs) and T-cell engager (TCE) therapeutics, with pharmaceutical companies continuing to commit substantial capital to preclinical and early-stage innovation. The Jazz Pharmaceuticals–AbCellera collaboration illustrates how differentiated antibody technologies can command significant financial commitments before entering clinical development. VERAXA Biotech AG is positioning its technology platform across both ADCs and T-cell engagers, two therapeutic modalities that continue to attract strategic partnerships and acquisitions. Platform technologies and individual drug candidates both represent potential avenues for future partnering, licensing, and collaboration agreements. Recent transactions across the sector demonstrate that pharmaceutical companies are actively seeking access to…

Continue Reading

WednesdayJul 01, 2026 10:30 am

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Delivers First Edge AI Intoxication Detection Kiosk Prototypes

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio kiosks use artificial intelligence and voice analysis to detect potential intoxication and fatigue in workplace environments. The company is targeting industries such as mining, aviation, construction, transportation, and law enforcement, where safety-sensitive operations require large-scale screening. MindBio’s AI models have been trained on more than 50 million data points and analyze over 140 acoustic markers associated with impairment. Prototype kiosks are entering testing, validation, and data-analysis phases, before broader commercial deployment. The company is positioning this important new technology as a faster and…

Continue Reading

WednesdayJul 01, 2026 9:45 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma executive co-chairman and co-founder Anthony Durkacz appeared as a guest on the BioMedWire Podcast. Durkacz outlined the company’s strategy for advancing Lucid-MS, the company’s lead drug candidate for multiple sclerosis. The Quantum BioPharma exec also provided an update on unbuzzd, the company’s innovative, clinically validated alcohol metabolism accelerator designed to help sober people up faster. Executive thought leadership has become an increasingly important component of corporate communications, particularly in highly specialized industries such as biotechnology. Through podcasts, interviews and other educational forums,…

Continue Reading

WednesdayJul 01, 2026 9:00 am

Rare Earths in 2026: Structural Deficits Open Ground for Junior Developers Like Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF)

Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) and may include paid advertising. The global rare earth elements market is projected to grow from roughly $14 billion in 2025 to more than $41 billion by 2034, driven by accelerating demand from EV traction motors, wind turbines, consumer electronics, and defense applications China continues to dominate rare earth mining and processing capacity, leaving Western manufacturers exposed to persistent supply concentration risk as governments push to build alternative supply chains Canamera Energy Metals raised approximately $10.2 million over four months ending March 2026 and is advancing active exploration…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000